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1. Introduction 
A majority of individuals reporting temporomandibular joint (TMJ) disorders have joint 
damage, inflammation or arthritis (Manfredini, Chiappe & Bosco, 2006; Plesh, Sinisi, 
Crawford & Gansky, 2005). The joint will show loss of extra-cellular matrix components in 
the articular cartilage and subchondral bone resulting in destruction of cartilage and bone, 
such processes lead to inflammation and exacerbation of joint tissue catabolism (Tanaka, 
Detamore & Mercuri, 2008). Matrix metalloproteinases 1 and 9 (MMP-1 and MMP-9) are two 
major enzymes that contribute to tissue catabolism and have been observed in patients with 
TMJ disorders (Kanyama, Kuboki, Kojima, Fujisawa, Hattori, Takigawa & Yamashita, 2000; 
Srinivas, Sorsa, Tjaderhane, Niemi, Raustia, Pernu, Teronen & Salo, 2001; Yoshida, 
Takatsuka, Hatada, Nakamura, Tanaka, Ueki, Nakagawa, Okada, Yamamoto & Fukuda, 
2006). Reversal of these disease processes and treatment of the joint to reduce pain are 
effective in the early stages of the disease, but treatment often fails to alleviate the severe, 
chronic pain caused by advanced joint degeneration (Gerwin, Hops & Lucke, 2006; Tanaka, 
Detamore & Mercuri, 2008). 
Treatment of TMJ osteoarthritis with intra-articular injections of non-steroidal anti-
inflammatory drugs (NSAIDs) and opiates into the superior joint space have shown efficacy 
(Bryant, Harrison, Hopper & Harris, 1999; Swift, Roszkowski, Alton & Hargreaves, 1998; 
Zuniga, Ibanez & Kozacko, 2007). Intra-articular administration versus systemic 
administration of NSAID or opiates would be advantageous for treatment of TMJ 
inflammation and pain because local administration avoids the ectopic effects seen with 
NSAIDs like rofecoxib (i.e., Vioxx) (Lin, Weisdorf, Solovey & Hebbel, 2000) or opiates. For 
example, nonselective NSAIDS can cause intestinal bleeding, whereas some selective 
cyclooxygenase-2 inhibitors have significant cardiovascular and renal safety risks (Davies & 
Jamali, 2004; Mukherjee, Nissen & Topol, 2001). Moreover, opioids frequently cause 
constipation, sedation, nausea, vomiting, and respiratory depression (Mercadante, 1999).  
Intra-articular injection remains controversial in light of decades of mixed reports 
demonstrating intra-articular injections either accelerate or trigger destruction of tissues 
within the TMJ and the surrounding area (Bjornland, Rorvik, Haanaes & Teige, 1994; 
Sugisaki, Ikai & Tanabe, 1995; Westesson, Eriksson & Liedberg, 1986). Recent reports 
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demonstrate that the risks of intra-articular TMJ injection can be minimized by utilizing 
magnetic resonance imaging (MRI) for visualizing the needle during the injection 
procedure (Fritz, Thomas, Tzaribachev, Horger, Claussen, Lewin & Pereira, 2009; 
Hayakawa, Kober, Otonari-Yamamoto, Otonari, Wakoh & Sano, 2007). Current treatment 
protocols that utilize intra-articular drug delivery can require frequent injections, 
increasing the risk of infection and damage to the joint and, in the event MRI or some 
other form of imaging is utilized, dramatically increase the expense of the procedure. 
Alternatively, if drug delivery could be sustained after a single injection these risks from a 
multi-injection protocol could be minimized. 
A variety of methods have been tested for sustained drug delivery in a joint space, including 
encapsulating or incorporating drugs into nano- or microparticles consisting of organic 
polymers (Deasy, 1994; Mountziaris, Kramer & Mikos, 2009). In this report we test a 
crosslinked fluid filled gelatin capsule for intra-articular injection. This capsule has a gelatin 
shell with a core of oil containing the drug ibuprofen or morphine. Other studies used 
uncrosslinked gelatin microcapsules, in contrast to our crosslinked capsules. The capsules 
were given orally but only released drug for 24-48 hours (Jizomoto, Kanaoka, Sugita & 
Hirano, 1993). Most intra-articular studies testing sustained release of NSAIDs utilized 
poly(lactide-co-glycolide) (PLGA) (Bozdag, Calis, Kas, Ercan, Peksoy & Hincal, 2001; 
Fernandez-Carballido, Herrero-Vanrell, Molina-Martinez & Pastoriza, 2004a; Fernandez-
Carballido, Herrero-Vanrell, Molina-Martinez & Pastoriza, 2004b; Liggins, Cruz, Min, Liang, 
Hunter & Burt, 2004; Puebla, Pastoriza, Barcia & Fernandez-Carballido, 2005; Tuncay, Calis, 
Kas, Ercan, Peksoy & Hincal, 2000). PLGA has a rigid structure and may be irritating to the 
joint when injected intra-articularly, particularly when smaller than 20 microns (Liggins, 
Cruz, Min, Liang, Hunter & Burt, 2004). Importantly, in vivo studies injecting solid gelatin 
spheres have shown that they do not induce an inflammatory response in vivo suggesting 
gelatin in these studies should not induce an immune response (Brown, Leong, Huang, 
Dalal, Green, Haimes, Jimenez & Bathon, 1998). 
Testing the rate of gelatin microcapsule degradation, as a result of MMP degradation, and 
the level of inflammation induced by the microcapsules in the TMJ are necessary. Also an 
important question to address was does sustained release improve pain reduction when 
administering NSAIDs or opiates to treat a TMJ disorder?  To address these questions we 
used a rat model for TMJ arthritis.  
In this model we inject the TMJ with the adjuvant complete Freund’s adjuvant (CFA) and 
the rat’s meal duration will lengthen in male and female rats as a result of this injection 
(Kerins, Carlson, Hinton, Grogan, Marr, Kramer, Spears & Bellinger, 2005; Kerins, Carlson, 
McIntosh & Bellinger, 2003; Kerins, Carlson, McIntosh & Bellinger, 2004; Kramer & 
Bellinger, 2009; Thut, Hermanstyne, Flake & Gold, 2007). Microcapsules containing vehicle 
or the NSAID ibuprofen or morphine were injected into the TMJ of rats that had no joint 
arthritis or had adjuvant (i.e., CFA) induce arthritis. Degradation of the microcapsules was 
monitored and the level of inflammatory cytokine IL-1β in the joint tissues was quantitated. 
In addition, the nociceptive response to the microcapsules loaded with vehicle or NSAID or 
morphine were measured in a non-arthritic and arthritic TMJ after intra-articular injection.  
2. Materials and methods 
2.1 Microcapsule production 
To produce the loaded microcapsules canola oil was sonicated in water to induce formation 
of droplets 20-50 micrometers in size. Before sonication the canola oil was mixed with 
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2.5µl/ml of 1mM Alexa 488 dye (Invitrogen, Carlsbad CA) dissolved in toluene. Or a 
saturated solution of ibuprofen in canola oil was used containing ~15% (w/v) ibuprofen. A 
solution of Type A gelatin with a Bloom strength of 300 was added after sonication. The 
collagen gelatin was allowed to coat the oil droplets such that 80% of the microcapsule mass 
was canola oil and 20% was a gelatin shell by weight. Amino acids in the gelatin coated oil 
droplets were then cross-linked by addition of 15% 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide) [EDC] (dry wt. of gelatin) to induce stable microcapsules. EDC is a water 
soluble carbodiimide usually obtained as the hydrochloride that can generally be used as a 
carboxyl activating agent for the coupling of primary amines to yield amide bonds between 
a free amine group (e.g., protein- or peptide-bound lysine) and the gamma-carboxamid 
group of protein- or peptide-bound glutamine. The cross-linking reaction was performed at 
room temperature for 12 hr. After crosslinking the microcapsules were washed 4 times with 
Tris Buffer pH 7.0, dried, sterilized with ethylene oxide and then hydrated with 0.9% saline. 
The morphine capsules were produced in a similar manner with some modifications. 
Morphine alkaloid crystals were ground to a small size (less than 50 microns) and 
suspended in canola oil. This suspension was emulsified in a solution of the gelatin at 60°C. 
A complexing agent (hexametaphosphate) was added to the aqueous phase and the pH was 
adjusted to approximately 4.75 with acetic acid to allow coacervation to occur. The 
microcapsules were crosslinked, lyophilized until dry and sterilized. 
2.2 Detection of Ibuprofen and morphine by HPLC   
Known weights of beads were dissolved in acetonitrile and analyzed via high performance 
liquid chromatography (HPLC) as follows. A six point calibration curve was prepared by 
serial dilution and HPLC analysis. The stock solution of 1mg/mL was prepared in 1:1 
deionized water (pH 2.5) and acetonitrile. Concentrations of 1, 5, 10, 25, 50 and 100 µg/mL 
were made in methanol. Samples of 20 µL were injected onto a C-18 column (Supelco 
Discovery C-18, 4.6 x 15 cm). The isocratic separation was carried out at 30°C using a mobile 
phase of 1:1 deionized water (pH 2.5) and acetonitrile. The flow rate was 2.0 ml/min with a 
run time of 10 minutes. Absorbance at 214 nm was taken using a Waters 486 UV detector. 
The absorbance of the sample was compared to a six-point standard curve from which 
concentration and percent loading in capsules was determined.  
2.3 In vitro assay for microcapsule degradation 
In 24 well tissue culture plates approximately 80,000 microcapsules were placed in each well 
with either 0.9% saline, 15 µg/ml CFA (paraffin oil/15g Mycobacterium tuberculosis) mixed 
in water, or a 50:50 mixture of 0.9% saline and 15 µg/ml CFA. A homogenate of the water 
and oil was created by passing the solution through a 20 gauge needle 5 times. The plates 
were placed in a 5% CO2 chamber at 37◦C. The microcapsules were counted in triplicate in a 
hemacytometer chamber 0, 5 and 10 days following addition to the different solutions.  
2.4 TMJ Injections 
The Baylor College of Dentistry Institutional Animal Care and Use Committee approved the 
experimental protocol. Male (250 grams) Sprague-Dawley rats from Harlan Industries, 
Houston, TX were kept on a 12:12 light/dark cycle with lights on at 08:00 hours. The 
animals were housed individually in our computerized feeding modules and given food 
and water ad libitum. They were acclimated to the surroundings for two days before 
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receiving injections. Prior to the TMJ injections, the rats were removed from their cages and 
anesthetized with a 5% gas flow of isoflurane. Following the TMJ injections and removal 
from anesthesia, the rats began freely moving within two minutes.  
2.4.1 Bead degradation study 
Saline or 15 µg of CFA in 15 µl was injected into the upper joint space of the TMJ followed 
by a second injection 24 hours later of 30 µl of dye loaded microcapsules (90 mg 
microcapsules [dry weight]/1 mlTris buffer or 0.9% saline) into the same location. The 
animals were sacrificed 5 hours (day 0), 5 and 10 days after injection of microcapsules and 
TMJ was removed en bloc, fixed in paraformaldehyde, sectioned and stained as described 
below.  
2.4.2 Microcapsules affect nociceptive response study  
Rats were injected with 30 µl 0.9% saline or 15 µg CFA and then 24 hours later the rats were 
injected with either saline or 30 µl of the microcapsule slurry (20% w/v) in 0.9% saline. 
Before and after injection of the microcapsules the meal duration was recorded. 
2.4.3 MMP effect on degradation study 
Rats were injected with 30 µl saline or 15 µg CFA or saline with an MMP inhibitor or CFA 
with an MMP inhibitor added and then 24 hours later these groups of rats were injected 
with 30 µl microcapsules or microcapsules plus the MMP inhibitor. The MMP inhibitor was 
a 1 µM solution of the MMP-2,9 inhibitor IV (EMD Biosciences, cataloge # 444274). In the 
first experiment the rats were sacrificed 0, 5 and 10 days following microcapsule injection, 
the TMJ was removed, sectioned and the microcapsules counted. In the second experiment 
the rats nociceptive response was assayed in the pellet feeders, as described below. 
2.4.4 Drug loaded microcapsules study 
Rats were injected into the upper joint space of the TMJ with a 30 µl slurry of 
microcapsules containing 15% ibuprofen or 1% morphine in oil or aslurry of 
microcapsules containing just oil. After twenty-four hours a portion of these animals were 
subdivided further; one group received bilateral injections of 0.9% saline (30 µl) and the 
other group received an injection of CFA into the upper joint space. Before and after 
injection the nociceptive response (i.e., meal duration) was assayed by placing the rats in 
pellet feeders. Also, on day 7 post-injection the TMJ tissue of a portion of these rats was 
harvested for quantitation of the cytokine IL-1β.  
2.5 Nociceptive assay  
The rats were housed individually in sound-attenuated chambers equipped with 
photobeam computer-activated pellet feeders (Med Assoc. Inc., East Fairfield, VT). The rats 
were given 45 mg rodent chow pellets (Product No. FO 165, Bioserv, Frenchtown, NJ). When 
a rat removes a pellet from the feeder trough, a photobeam placed at the bottom of the 
trough is no longer blocked, signaling the computer to drop another pellet, record the date 
and time, and keep a running tally of the total daily food consumption. The computer 
record of pellets dropped over time establishes the meal duration, which is a continuous 
non-invasive biological marker of TMJ nociception (surface and deep) in undisturbed male 
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and female rats (Kerins, Carlson, Hinton, Grogan, Marr, Kramer, Spears & Bellinger, 2005; 
Kerins, Carlson, McIntosh & Bellinger, 2003).  
2.6 Animals and tissue preparation 
Rats were sacrificed within 20 sec to minimize stress. For the cytokine study the TMJ 
anterior, disc, retrodiscal and synovium were dissected from one side by performing a 
superficial, horizontal skin incision parallel and just inferior to the zygomatic arch. The 
masseter and temporalis muscles were cut away from the arch and the ramus of the 
mandible so that the arch could be removed with ronjeurs. The neck of the condyle was 
grasped with hemostats and the condylar neck fractured to allow removal of any remaining 
musculature and access to the anterior, disc, retrodiscal and synovial tissues. Dissected TMJ 
tissue was excised from the posterior neck of the condyle, and all anterior tissue, articular 
disc, retrodiscal tissue and synovium were removed, placed in liquid nitrogen and stored at 
–80°C. To count the number of microcapsules in the TMJ a 0.5 cm cube of TMJ tissue 
centered on the condyle from the other side was removed and placed in 4% 
paraformaldehyde at 4°C overnight. The tissue was then decalcified in 0.5 M EDTA in a 
Pelco microwave (Ted Pella Inc., Redding CA) for 2 weeks, frozen and 20 m sections were 
cut and mounted on Superfrost glass slides (Fisher Scientific, Pittsburgh, PA). Every 5th 
section was stained with hematoxylin and eosin for counting and a small number of the 
slides were mounted with fluormount and DAPI. Microcapsules were counted on every 5th 
section to obtain a representative sample through the entire TMJ region (West & Slomanka, 
2001). The fluorescent signal was imaged using MetaMorph Imaging System software 
(Molecular Devices Corporation, Sunnyvale, CA), a Photometrics CoolSnap K4 CCD camera 
(Roper Scientific, Inc, Duluth, GA) and a fluorescent microscope using a DAPI filter with 
excitation between 395-410 nm and an emission between 450-470 nm, as well as, a FITC filter 
with excitation between 490-505 nm and an emission between 515-545 nm.  
2.7 Cytokine assay 
The TMJ tissue was homogenized in buffer (75 mM potassium acetate pH 7.4, 300 mM 
NaCL, 10 mM EDTA, 0.25% Triton X-100, protease inhibitors). It has previously been shown 
that TMJ-injected CFA can increase IL-1β (Kerins, Carlson, McIntosh & Bellinger, 2003) . 
Therefore, the cytokines IL-1 were quantitated from this homogenate using ELISA kits 
according to the manufacturer's directions (R&D Systems, Minneapolis, MN). 
3. Statistics 
The data were analyzed using a two-way analysis of variance with repeated measurement. 
Independent variables were treatment and time. The dependent variable was either the bead 
count or meal duration. The data found to be significant were further analyzed by 
Bonferonni pos-hoc test. 
4. Results 
Images of the microcapsules in solution show that the capsules average size was 30 µm (Fig. 
1A) and that the inside of the microcapsule is loaded with the dye/mineral oil mixture (Fig. 
1B). About 80% of the mass of these microcapsules is the fluid mineral oil and about 20% of 
the mass consists of the gelatin shell. 
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Fig. 1. Gelatin microcapsules containing canola oil mixed with Alexa 488 dye range in size 
between 15-30 micrometers. Microcapsules are loaded with canola oil (80% by weight) mixed 
with 1mM Alexa 488 dye. A) Bright field image of the microcapsules in solution. B) 
Fluorescent image of the same microcapsules before injection into the TMJ. Bar equals 100 µM. 
To initially assess the degradation characteristics of the gelatin shell the microcapsules 
were placed in 24 well tissue culture plates containing saline and CFA solutions. Over a 
period of 10 days the beads did significantly degrade in a mixture of isotonic saline and 15 
µg of CFA (Fig. 2).  
Injection of dye loaded microcapsules (30 µl) into the upper joint space, a region between 
the articular fossa and condyle (Fig. 3A) produced an area of beads 2-3 mm in diameter 
(dotted line, Fig. 3B) in the upper joint space of the rat TMJ. Cells (e.g. neutrophils) were 
adjacent to the microcapsules 5 hours after injection (blue nuclei, Fig. 3C-E). In the TMJ 
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the microcapsules appeared to degrade as a result of inducing an arthritic response (i.e., 
CFA injection), compare Fig. 4A to Fig. 4B and compare Fig. 4C to Fig. 4D. Time also 
reduced the number of microcapsules in the joint, compare 5 day and 10 day saline 
injected rats (compare Fig. 4A to Fig. 4C) and 5 day and 10 day CFA injected rats 
(compare Fig. 4B to Fig. 4D). A significant decrease in the number of intact beads was 
observed in the inflamed TMJ when comparing the 5 day time point to the 10 day time 
point (Fig. 4E). 
 
 
 
 
 
 
 
 
 
Fig. 2. Microcapsule breakdown in vitro. Microcapsules (approximately 80,000) were placed 
in 200 µl of three different solutions at a temperature of 37°C and the degradation of the 
microcapsules was monitored by counting the number of intact microcapsules remaining 
after 1, 5 and 10 days. The solutions the microcapsules were placed in consisted of either 1) 
0.9% saline or 2) 15 µg/ml of CFA/water homogenate or 3) a 50%/50% homogenate of 0.9% 
saline and 15 µg/ml CFA. At each time point a 10 µl aliquote was removed and the number 
of microcapsules was counted in triplicate in a hemacytometer chamber. Values are the 
mean ± SEM.  
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Fig. 3. Injection of gelatin microcapsules containing canola oil with Alexa 488 dye were 
injected into the upper joint space of a rat temporomandibular joint (TMJ). A) Sagittal view 
of a rat skull, arrows point to the TMJ condyle and articular fossa. In this experiment the 
TMJ upper joint space was injected with 30 µl of dye loaded microcapsules (90 mg 
microcapsules [dry weight] in 1 ml of Tris buffer or 0.9% saline and then the rats were 
sacrificed 5 hours later. B) Saggittal section of a rat TMJ 5 hours after injection of 
microcapsules into the upper joint space (arrow) stained with hemotoxylin and eosin. 
Dotted line in the upper joint space outlines the region containing the injected 
microcapsules. C) High magnification image of boxed region in panel B. D) Fluorescent 
image of Alexa 488 loaded microcapsules 5 hours after injection into the TMJ. Green is the 
Alexa 488 loaded microcapsules and blue is the DAPI stained cell nuclei. E) High 
magnification of image from panel D. Bar in panel B equals 1 mm and bar in panel D equals 
100 µm. 
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Fig. 4. Microcapsule breakdown in a non-arthritic and arthritic TMJ. Saline or 15 µg of CFA 
in 15 µl was injected into the TMJ followed by a second injection 24 hours later of 30 µl of 
dye loaded microcapsules. Microcapsules in the upper joint space/synovial tissue were 
imaged in sagittal sections of the TMJ tissue 5 and 10 days after injection of microcapsules. 
Images were captured 5 days after injecting the TMJ with microcapsules and saline (A) or 
CFA (B). Microcapsules in the upper joint space/synovial tissue was imaged 10 days after 
injection of microcapsules in a joint previously injected with saline (C) or CFA (D). The 
histogram below indicates the number of microcapsules counted per joint in rats sacrificed 
0, 5 and 10 days after injection. There were 5 animals per group. Asterisk indicates P<0.05. 
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We next asked the question, would injection of microcapsules into the TMJ induce a pain 
response in the rat with a non-arthritic or an arthritic joint. To test the response to 
microcapsule injection we measured a behavioral correlate of nociception (meal duration) 
before and after injecting microcapsules into the TMJ of a rat previously injected with saline 
(non-arthritis) or CFA (arthritic). Microcapsule injection did not significantly increase the 
pain response in either the non-arthritic or arthritic joint (Fig. 5). 
 
 
 
 
 
 
 
 
 
Fig. 5. Nociceptive response after injecting microcapsules into a non-arthritic and arthritic 
TMJ. Rats were injected with 30 µl 0.9% saline or 15 µg CFA (CFA inj) and then 24 hours 
later the rats were injected with either saline or 30 µl microcapsules in 0.9% saline. After 
injection of the microcapsules the meal duration was recorded for 10 days (1 through 10). 
There were 8 animals per group. *=P<0.05, **=P<0.01 when comparing the CFA + saline 
group to the saline + saline group and when comparing the CFA + microcapsule group to 
the saline + microcapsule group.  
To test that the breakdown of beads in vivo may be due the presence of MMP-2 and 
MMP-9 we injected the microcapsules with an MMP-2/9 inhibitor. The number of 
microcapsules decreased over time in vivo but addition of a MMP-2/9 inhibitor had no 
significant effect on microcapsules degradation after injection into a rat TMJ (Fig. 6). The 
inhibition of the MMP-2/9 also did not affect the nociceptive response after injecting the 
TMJ with microcapsules (Fig. 7). 
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Fig. 6. Effect of metalloprotease inhibitor 2 and 9 on microcapsule breakdown in vivo  Rats 
were injected with saline or CFA or saline with an MMP inhibitor or CFA with an MMP 
inhibitor added and then 24 hours later these groups of rats were injected with 30 µl 
microcapsules or microcapsules plus MMP inhibitor. All injections were into the superior 
joint space of the TMJ. The inhibitor was a 1 µM solution of the MMP-2/9 inhibitor IV. The 
histogram shows the total number of beads per joint after 0, 5 and 10 days after bead 
injection. There were 3-5 animals per group. *=P<0.05. 
 
 
Fig. 7. Nociceptive response after injecting microcapsules along with metalloprotease 
inhibitors Rats were injected into the upper joint space of the TMJ with 30 µl saline or 15 µg 
CFA (CFA inj), some in combination with a MMP-2/9 inhibitor. One day after this injection 
a second 30 µl injection of microcapsules or microcapsules containing MMP-2/9 inhibitor 
was performed. Before and after injection the meal duration was recorded. No inj= before 
animal were injected. There were 8 animals per group. *=P<0.05, **=P<0.01, ***=P<0.001 
when comparing CFA injected rats to the saline injected rats. 
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Ibuprofen drug loaded microcapsules did not significantly affect the nociceptive response 
(Fig. 8A) or the immune response (Fig. 8B) of CFA injected rats. Morphine loaded 
microcapsules did significantly decrease the nociceptive response (p<0.05, days 4 and 5) 
and post-hoc testing showed a significant decrease on the fourth day post-CFA injection 
(Fig. 8A).  
 
 
Fig. 8. Nociceptive and inflammatory response after injecting microcapsules containing 
ibuprofen or morphine. Rats TMJs were injected with a 30 µl solution of microcapsules 
(bead inj). The microcapsules contained oil (Blank microcapsules) or oil with 15% ibuprofen 
(Ibuprofen microcapsules) or oil containing 1% morphine (Morphine microcapsules). 24 
hours after microcapsule injection the rats were subdivided further for TMJ injection of 
either saline or 15 µg CFA (CFA inj). A) Before and 8 days after injection of the saline/CFA 
the daily meal duration was recorded. There were 8 animals in each of the four treatment 
groups. B)  The amount of IL-1β in the TMJ retrodiscal, synovial and disc tissue 7 days after 
injection with microcapsules. There were 3-4 animals in each of the four treatment groups 
for the cytokine analysis. 
5. Discussion 
Gelatin microcapsules have the capability for sustained drug release after intra-articular 
injection (Inoue, Takahashi, Arai, Tonomura, Sakao, Saito, Fujioka, Fujiwara, Tabata & 
Kubo, 2006; Lu, Zhang, Sun & Zhong, 2007; Saito, Takahashi, Arai, Inoue, Sakao, Tonomura, 
Honjo, Nakagawa, Inoue, Tabata & Kubo, 2009). Sustained drug delivery into a diseased 
TMJ has the potential to improve the treatment of TMJ pain and inflammation. In this report 
a rat model of TMJ inflammatory arthritis was used and we tested the effect of intra-
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articularly injected gelatin microcapsules on the nociceptive response as well as on the 
inflammatory response. Loading the gelatin microcapsules with the ibuprofen or morphine 
was accomplished because we hypothesized that intra-articular injection of drug loaded 
beads would reduce the nociceptive response. We determined that gelatin microcapsules do 
not increase IL-1β levels in the disc and synovial tissues after injection into the TMJ. Nor do 
the capsules increase the nociceptive response in an arthritic joint. Importantly, injection of 
morphine but not ibuprofen loaded microcapsules decreased the nociceptive response of a 
rat with an arthritic TMJ. Because injection of microcapsules loaded with morphine 
decreased the nociceptive response of a rat with inflammatory arthritis we expect that the 
microcapsules will amealorate the pain response in patients with TMJ disease.  
5.1 TMJ intra-articular model for testing microcapsules 
The premise of our animal (i.e., meal duration) model is that the CFA induced TMJ pain 
would affect the rat, such that, when a hungry animal initiated a meal the animal would eat 
slowly due to the TMJ pain associated with the movement of the mandible during the 
chewing process. This is exactly what we observed following bilateral TMJ CFA injections in 
males and females, i.e., the rats had longer meal durations (Harper, Kerins, Talwar, Spears, 
Hutchins, Carlson, McIntosh & Bellinger, 2000; Kerins, Carlson, Hinton, Grogan, Marr, 
Kramer, Spears & Bellinger, 2005; Kerins, Carlson, McIntosh & Bellinger, 2003). Support that 
meal duration is a measure for orofacial pain it that when ibuprofen is administered directly 
into a inflamed, CFA-injected TMJ meal duration was normal in both male and female rats 
(Kerins, Carlson, McIntosh & Bellinger, 2003). Our selection of CFA was made because it 
produces a persistent arthritic pain response that last for over two weeks (Hill, Bellinger, 
Spears, Hutchins, Kerins & Kramer, 2007; Ren, 1999). Thus, of all the agents, CFA was best 
when trying to establish long duration pain. Injection of CFA into the TMJ significantly 
lengthened meal duration in rats, while the same amount of CFA in the knee did not affect 
meal duration (Kerins, Carlson, Hinton, Grogan, Marr, Kramer, Spears & Bellinger, 2005) 
indicating meal duration is a specific measure of orofacial pain. Interestingly IL-1β remained 
significantly elevated in the TMJ of the ibuprofen treated animals injected with CFA (Kerins, 
Carlson, McIntosh & Bellinger, 2003), suggesting that some inflammation from the CFA 
injection remained. In another study, cyclooxgenase-II (COX-2) inhibitors normalized meal 
duration in rats after CFA injection (Kerins, Carlson, McIntosh & Bellinger, 2004). In this 
study the COX-2 inhibitor also attenuated the inflammation, i.e., TMJ tissue IL-1 
normalized (Kerins, Carlson, McIntosh & Bellinger, 2004). In still another study, rats were 
given capsaicin or vehicle at 2 and 10 days of age; capsaicin permanently destroyed afferent 
nociceptive fibers in these animals (Bellinger, Spears, King, Dahm, Hutchins, Kerins & 
Kramer, 2007). When these male rats reached adulthood saline or CFA was injected into the 
TMJ and their meal duration was measured. Capsaicin treatment alone had no effect on 
meal duration, because saline injected, non-capsaicin treated rats had the same meal 
duration as saline injected, capsaicin treated rats. Non-capsaicin treated rats injected with 
CFA had longer meal durations than rats that were pre-treated with capsaicin, which 
demonstrated meal duration after CFA injection was normalized due to a capsaicin-induced 
loss of afferent nociceptive neuronal fibers (Bellinger, Spears, King, Dahm, Hutchins, Kerins 
& Kramer, 2007). The lack of change in meal duration in these capsaicin treated male rats 
occurred despite CFA inducing greater TMJ swelling, which demonstrated that the physical 
and mechanical changes in the inflamed TMJ synovial joint did not affect meal duration 
measurements. Another rationale for suggesting that meal duration is a measure of 
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nociception stems from the finding that eating is impaired in patients with TMD (Haketa, 
Kino, Sugisaki, Amemori, Ishikawa, Shibuya, Sato & Yoshida, 2006) and from a clinical 
study of juvenile rheumatoid arthritic children (Harper, Brown, Triplett, Villasenor & 
Gatchel, 2000) that examined chewing performance as an objective measure of masticatory 
function. It showed that the juvenile rheumatoid arthritic children with TMD symptoms 
changed their chewing habits presumably to “guard” against pain. Most recently, meal 
duration in the rat was shown to be increased over the course of a week following pulp 
exposures demonstrating meal duration can also be used as a measure of tooth nociception 
(Bellinger, He & Kramer, 2010). 
5.2 Sustained drug release by gelatin is safe and effective 
Gelatin microcapsules are one type of sustained drug release mechanism that incorporates a 
shell of gelatin around a core of oil containing drug. One  advantage of gelatin is it has been 
shown to be a safe means for sustained drug delivery because in vivo there is no 
inflammatory response (Brown, Leong, Huang, Dalal, Green, Haimes, Jimenez & Bathon, 
1998; Tuncay, Calis, Kas, Ercan, Peksoy & Hincal, 2000) consistent with our result in the TMJ 
of a rat that showed injection of microcapsules did not increase the nociceptive response nor 
increased IL-1β levels in the TMJ. Studies using a shell of gelatin encapsulating oil 
containing drug demonstrated that uncrosslinked gelatin was effective when given orally 
(Jizomoto, Kanaoka, Sugita & Hirano, 1993). A previous pharmacokinetic study injecting 
gelatin microspheres containing NSAID show that the intra-articular concentration of 
NSAID was 8-fold higher 8 hours after injection versus the concentration of NSAID in a joint 
injected with a non-encapsulated solution of NSAID (Lu, Zhang, Sun & Zhong, 2007). 
Another recent study in a rabbit model indicated that intra-articular delivery of basic 
fibroblast growth factor or platelets via gelatin microspheres improved knee joint swelling, 
proteoglycan expression, and histological appearance of arthritic knee tissue (Inoue, 
Takahashi, Arai, Tonomura, Sakao, Saito, Fujioka, Fujiwara, Tabata & Kubo, 2006; Saito, 
Takahashi, Arai, Inoue, Sakao, Tonomura, Honjo, Nakagawa, Inoue, Tabata & Kubo, 2009). 
Our work is consistent with these results demonstrating microcapsule drug release can 
ameliorate arthritic TMJ pain. Future work would focus on encapsulating alternative drugs 
shown to be effective in relieving TMJ pain, such as mepivacaine (Zuniga, Ibanez & 
Kozacko, 2007).  
5.3 Microcapsule size and thickness for in vivo injection 
Thickness of the microcapsule wall can be varied and the timing of drug release would be 
based on the capsule cell wall thickness. What is important to keep in mind is that the 
microcapsules for this application need to be injectable and thus the diameter should not 
exceed the inner bore of the needle (e.g. 165 µM for a 29 gauge needle). As the wall of the 
bead becomes thicker the amount of loaded drug decreases thus, you inject less drug when 
using beads with a thicker wall diameter. Thus, a balance between the amount of time you 
want before drug release and the total amount of drug administered must be obtained. The 
diameter of the sphere is also important, with spheres greater than 26 µM remaining in the 
interstitial fluid of the tissue because they are not phagocytosed by cells (e.g., macrophages) 
(Horisawa, Kubota, Tuboi, Sato, Yamamoto, Takeuchi & Kawashima, 2002). The optimal 
size range for intra-articular drug delivery systems is application specific (Horisawa, Hirota, 
Kawazoe, Yamada, Yamamoto, Takeuchi & Kawashima, 2002; Horisawa, Kubota, Tuboi, 
Sato, Yamamoto, Takeuchi & Kawashima, 2002; Liggins, Cruz, Min, Liang, Hunter & Burt, 
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2004)  but in this intra-articular paradigm we did not want intracellular drug release thus 
the bead diameter was approximately 30 µM. 
In conclusion drug loaded gelatin microcapsules reduce the nociceptive response of an 
arthritic TMJ. These microcapsules are expected to be useful not only for the treatment of 
pain but also to modify the joint environment prior to implantation by delivering pro-
regenerative signals in a spatially and temporally controlled fashion. The limitations of 
current therapeutic strategies for TMJ disorders have led to increased interest in tissue 
engineering strategies, which combine cells, bioactive factors, and implantable scaffolds to 
trigger joint regeneration (Detamore & Athanasiou, 2003). In addition to the added benefit 
of sustained drug release local administration of drug has the added benefit of avoiding 
systemic drug release which can result in ectopic effects.  
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